These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32485225)

  • 21. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
    Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
    de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
    Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
    Berdaï D; Hotton JM; Lechat P;
    Therapie; 2010; 65(4):329-34. PubMed ID: 20854755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathways to faster access to medicines.
    Drug Ther Bull; 2018 Aug; 56(8):93-96. PubMed ID: 30135065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
    Mulder J; Verjans R; Verbaanderd C; Pean E; Weemers J; Leufkens HGM; Pignatti F; de Boer A; Voest EE; Stoyanova-Beninska VV; Pasmooij AMG
    Front Med (Lausanne); 2021; 8():790782. PubMed ID: 34957158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.